10.29 USD
▲+0.13+2.69%
盘后 10.03 +0.05%
2026-08-03
市值
$3.44B
市盈率
—
EPS
-0.02
股息率
—
52 周区间
6.28 – 14.27
成交量
116.83K
Beta
0.63
目标价
20.83
52W 低 6.2852W 高 14.27
价格走势
公司简介
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ...